Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ARIAD Pharmaceuticals ARIA

"ARIAD Pharmaceuticals Inc is an oncology company. The Company is engaged in transforming the lives of cancer patients with breakthrough medicines. It commercializes & develops products and product candidates including Iclusig, Brigatinib, and AP32788."
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (NDAQ:ARIA)

ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency

Business Wire February 6, 2017

Watch These 10 Huge Put Purchases In Tuesday Trade

Benzinga.com  January 31, 2017

Watch These 10 Huge Put Purchases In Friday Trade

Benzinga.com  January 27, 2017

Takeda's Speculative Interest In Synergy Soothes Stomach Pains; Canaccord Says Buy

Benzinga.com  January 25, 2017

Ariad Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of ARIA Shareholders

PR Newswire January 18, 2017

ARIAD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of ARIAD Pharmaceuticals, Inc. (ARIA) Over the Proposed Sale of the Company to Takeda Pharmaceutical Company Limited

PR Newswire January 13, 2017

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of ARIAD Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

Business Wire January 12, 2017

Harwood Feffer LLP Announces Investigation of ARIAD Pharmaceuticals, Inc.

PR Newswire January 9, 2017

Mid-Afternoon Market Update: Ariad Pharmaceuticals Surges On Acquisition News; Stage Stores Shares Slide

Benzinga.com  January 9, 2017

Opinion & Analysis (NDAQ:ARIA)

No current opinion is available.

Bullboard Posts (NDAQ:ARIA)

CNBC

Mentioned on CNBC's Fast Money as a takeout target now that an activist investor in Sarissa mgmt (Alex Denner) is on the BOD &...
Carlos66 - May 6, 2015

seems like an investment to me too..

Its been holding steady at 8 bucks ,,so i believe this is a point of resistance,,,,i am holding a few at 8.5o but am holding patiently,,,...
sam1221 - January 28, 2014

I am In

Been outta buying stocks for a while but I am back, and I like ARIA will wet my feet with this. I think somethin is about to move on this...
ablekaak - January 27, 2014

Very Insightful during Investor-and-Analyst-Meeting

Updates on clinical and safety data from the AP26113 trial & more..  [url=http://www.earningsimpact.com/Transcript/82369/ARIA...
EarningsImpact1 - July 26, 2013

2...2...2

check option. nothing to do with anything. pure play.
conspiTheory - December 19, 2009

dont forget he trend

duh and the times to make their next phase.
conspiTheory - December 10, 2009